Literature DB >> 24356808

The influence of comedication on tacrolimus blood concentration in patients subjected to kidney transplantation: a retrospective study.

Neven Vavic1, Nemanja Rancic, Viktorija Dragojevic-Simic, Biljana Draskovic-Pavlovic, Dubravko Bokonjic, Ljiljana Ignjatovic, Momir Mikov.   

Abstract

Tacrolimus is an immunosuppressant used for the prevention of kidney allograft rejection. The effects of comedication on tacrolimus trough concentrations (TTC) in kidney transplant recipients, subjected to basic immunosuppressant regime consisting of tacrolimus, corticosteroids and mycophenolate mofetil were investigated. This retrospective case series study involved 208 of these patients, with the outpatient examination recorded in the database of patients, at the unit of monitoring, with a total of 5,011 such examinations. Binary logistic regression analysis has shown that calcium channel blockers, diuretics and proton pump inhibitors (PPIs) significantly affected TTC (p < 0.001). PPIs significantly increased the number of examinations in which the TTC were in the recommended therapeutic range (from 5 to 15 ng/ml), as well as over the therapeutic range (p < 0.0001). When calcium channel blockers were added to PPIs, even more pronounced effect was obtained in comparison to triple-drug therapy only (p < 0.0001). In case a diuretic was given with a PPI, a significantly increased number of examinations with subtherapeutic TTC was observed when compared with PPI only (p = 0.0203). The combination of calcium channel blockers, diuretics and PPIs resulted in the number of examinations with TTC in the recommended therapeutic range not being different from the number of examinations with TTC in the triple-drug therapy only (p = 0.3829). β-adrenergic antagonists can be administered without fear of affecting the tacrolimus optimal therapeutic concentrations. This was confirmed with all combinations of the examined drugs used in patients subjected to kidney transplantation concomitantly with β blockers.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24356808     DOI: 10.1007/s13318-013-0168-3

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  64 in total

1.  Low tacrolimus concentrations and increased risk of early acute rejection in adult renal transplantation.

Authors:  C Staatz; P Taylor; S Tett
Journal:  Nephrol Dial Transplant       Date:  2001-09       Impact factor: 5.992

2.  Quantification of tacrolimus and three demethylated metabolites in human whole blood using LC-ESI-MS/MS.

Authors:  Ilse R Dubbelboer; Anton Pohanka; Rana Said; Staffan Rosenborg; Olof Beck
Journal:  Ther Drug Monit       Date:  2012-04       Impact factor: 3.681

3.  Monoclonal antibodies in renal transplantation: old and new.

Authors:  Dirk R J Kuypers; Yves F C Vanrenterghem
Journal:  Nephrol Dial Transplant       Date:  2004-02       Impact factor: 5.992

4.  Gender differences in pharmacokinetics of tacrolimus and their clinical significance in kidney transplant recipients.

Authors:  Radmila Velicković-Radovanović; Momir Mikov; Goran Paunović; Vidojko Djordjević; Mariola Stojanović; Tatjana Cvetković; Aleksandra Catić- Djordjević
Journal:  Gend Med       Date:  2011-02

5.  Relationship of FK506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation.

Authors:  R P Kershner; W E Fitzsimmons
Journal:  Transplantation       Date:  1996-10-15       Impact factor: 4.939

6.  Pharmacogenetic determinants for interindividual difference of tacrolimus pharmacokinetics 1 year after renal transplantation.

Authors:  M Miura; T Niioka; H Kagaya; M Saito; M Hayakari; T Habuchi; S Satoh
Journal:  J Clin Pharm Ther       Date:  2011-04       Impact factor: 2.512

7.  Diltiazem increases tacrolimus concentrations.

Authors:  M F Hebert; A Y Lam
Journal:  Ann Pharmacother       Date:  1999-06       Impact factor: 3.154

Review 8.  Drug-drug interactions of beta-adrenoceptor blockers.

Authors:  Otto-Erich Brodde; Heyo K Kroemer
Journal:  Arzneimittelforschung       Date:  2003

9.  Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients.

Authors:  Eric Thervet; Dany Anglicheau; Barry King; Marie-Hélène Schlageter; Bruno Cassinat; Philippe Beaune; Christophe Legendre; Ann K Daly
Journal:  Transplantation       Date:  2003-10-27       Impact factor: 4.939

Review 10.  Mechanisms of clinically relevant drug interactions associated with tacrolimus.

Authors:  Uwe Christians; Wolfgang Jacobsen; Leslie Z Benet; Alfonso Lampen
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

View more
  4 in total

1.  Tacrolimus Utilization and Expenditure in Serbia.

Authors:  Nemanja Rancic; Neven Vavic; Katarina Obrencevic; Filip Pilipovic; Viktorija Dragojevic-Simic
Journal:  Front Public Health       Date:  2017-11-07

Review 2.  Economic Evaluation of Pharmacogenetic Tests in Patients Subjected to Renal Transplantation: A Review of Literature.

Authors:  Nemanja Rancic; Viktorija Dragojevic-Simic; Neven Vavic; Aleksandra Kovacevic; Zoran Segrt; Natasa Djordjevic
Journal:  Front Public Health       Date:  2016-08-31

3.  Which Kidney Transplant Recipients Can Benefit from the Initial Tacrolimus Dose Reduction?

Authors:  Kinga Krzyżowska; Aureliusz Kolonko; Piotr Giza; Jerzy Chudek; Andrzej Więcek
Journal:  Biomed Res Int       Date:  2018-01-30       Impact factor: 3.411

4.  The Relationship between Initial Tacrolimus Metabolism Rate and Recipients Body Composition in Kidney Transplantation.

Authors:  Aureliusz Kolonko; Patrycja Pokora; Natalia Słabiak-Błaż; Beata Czerwieńska; Henryk Karkoszka; Piotr Kuczera; Grzegorz Piecha; Andrzej Więcek
Journal:  J Clin Med       Date:  2021-12-10       Impact factor: 4.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.